Home/Valar Labs/Trevor Royce, MD
TR

Trevor Royce, MD

Chief Medical Officer

Valar Labs

Therapeutic Areas

Valar Labs Pipeline

DrugIndicationPhase
VestaBladder Cancer (BCG therapy response)Commercial
CHAI BiomarkerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)Development/Validation